STING Agonist Solid Tumors
TAK-676 is a selective agonist of STimulator of INterferon Genes (STING), a critical molecule for initiating both innate and adaptive immunity via induction of type I interferon response
STING signaling activated inflammation
Stimulator of INterferon Genes mediated Type I IFN response plays a core role in:
- Viral clearance
- Bacterial response
- Apoptosis of dying cells
STING signaling in cancer leads to two primary anti-tumors effects
- Activation of innate cells (macrophages, DCs) to produce IFN and “cross-primte” CD8 T cells and also activate NK cells that traffic to tumor
- Induction of tumor cell apoptosis (minor - in tumors with high STING)
An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
1. Takeda, Data on file.
2. O'Neill. Science. 2013.
Takeda Live Chat
On exiting, all chat history will be cleared